Small Molecules

To our knowledge, no firm has handled more complex Hatch-Waxman patent infringement actions in the past ten years. Since the firm’s inception in 2004, RMMS has handled over 200 Hatch-Waxman and related pharmaceutical litigation matters (including declaratory judgment, patent infringement, Administrative Procedure Act (APA), and commercial dispute matters) involving at least 130 different drug products for at least 20 pharmaceutical clients.

RMMS litigation attorneys are armed with significant pre-trial, trial, and appellate skills. Our attorneys practice regularly in federal courts throughout the country, and have extensive experience litigating in jurisdictions that hear large numbers of patent and Hatch-Waxman cases, including district courts in Delaware, New Jersey, New York, Maryland, Virginia, Texas, North Carolina, and California. Our attorneys also regularly appear before the U.S. Court of Appeals for the Federal Circuit.

We understand that patent litigation is not an end-game, and that the business decisions made throughout the entire product and patent evaluation, regulatory review, litigation, and commercialization process are equally critical to the company’s strategic plans involving any one product or group of products. Our goals are aligned with those of our clients: to ensure that each client obtains value from its applications, whether through the eventual commercial marketing of the product, the sale or assignment of the asset, or relationship-building with other companies through joint development agreements, active pharmaceutical ingredient (API) and finished dosage form supply agreements, licensing agreements, and co-promotion and marketing agreements.